The high prevalence and great diversity of p53 tumor suppressor gene mutations in human tumors call for development of therapeutic molecules that rescue function of aberrant p53 protein. P53 mutations also oer new approaches to the study of the origins of mutations in human cancer. An experimental mouse model with a genetically modi®ed but normal functioning p53 gene harboring the human rather than the murine core domain, would be of considerable bene®t to research on both cancer therapeutics and etiology; however, it is uncertain whether such mice would permit biological functions of p53 to be retained. Using a Cre/lox P genetargeting approach, we have constructed a human p53 knock-in (hupki) mouse strain in which exons 4 ± 9 of the endogenous mouse p53 allele were replaced with the homologous, normal human p53 gene sequence. The chimeric p53 allele (p53 KI ) is properly spliced, transcribed in various tissues at levels equivalent to wild-type mice, and yields cDNA with the anticipated sequence, that is, with a core domain matching that of humans. The hupki p53 protein binds to p53 consensus sequences in gel mobility shift assays and accumulates in the nucleus of hupki ®broblasts in response to UV irradiation, as is characteristic of wild-type p53. Induction of various p53-regulated genes in spleen of g-irradiated homozygous hupki mice (p53 KI/KI ), and the kinetics of p53-dependent apoptosis in thymocytes are similar to results with wildtype (p53 +/+ ) mice, further indicating normal p53 pathway function in the hupki strain. The mice are phenotypically normal and do not develop spontaneous tumors at an early age, in contrast to knock-out (p53 7/7 ) strains with a defective p53 gene. The chimeric (p53 KI ) allele thus appears to provide a biological equivalent to the endogenous murine (p53
Introduction
The p53 protein is dysfunctional or absent in the majority of human tumors, primarily due to single missense point mutations in the gene (Vogelstein and Kinzler, 1992; Hainaut and Hollstein, 2000) . Most of the 15 000 published human tumor mutations lie in the core (DNA-binding) domain (Harris and Hollstein, 1993; Lane, 1999) , and reduce or abolish the ability of the p53 protein to bind to recognition sequences of p53-responsive genes and stimulate transcription. To investigate factors contributing to p53 tumor mutations in tumors, published p53 mutation spectra of human cancers can be compared with experimentally induced tumor p53 mutations in standard laboratory mouse strains (reviewed in Hollstein et al., 1999) ; however, there has been to date no practical approach to the experimental induction of mutations in the human p53 gene sequence in vivo. The core domains of the mouse and human p53 genes dier at 15% of base residues. Since mutation patterns are dictated in the ®rst instance by the exact DNA base context, even subtle sequence dierences can modify mutation spectra. Expectedly, speci®c carcinogen-induced p53 tumor mutations do not accumulate at precisely the same sites in the mouse and in humans (Dumaz et al., 1997) . These considerations call for generation of mouse strain with human p53 sequences, which would be particularly relevant if the modi®ed gene were transcribed at normal levels and encoded a functional protein.
A human p53 knock-in mouse strain of this nature would also lend itself to investigation of molecules designed to target the tumor suppressor protein. While mice with an unmodi®ed endogenous p53 gene can be used to test the ecacy of drugs targeting the mouse p53 protein, human/mouse species sequence dierences complicate assessment of experimental results for humans. Although the similarity between mouse and human p53 is remarkably high at the amino acid level (91% homology in the core domain), single residue dierences may aect response to drugs designed either to restore DNA-binding activity of the common human tumor missense mutants (Foster et al., 1999) , or conversely, to block wild-type protein function temporarily in order to reduce side eects of chemoor radiation therapy (Komarov et al., 1999) . Genetically engineered mice with a`humanized' p53 gene thus would provide a new dimension to existing in vivo test systems not only for mutagenesis studies but also for pre-clinical testing of p53-modifying drugs; however, it remains to be shown whether in this chimeric context, p53 would continue to exercise its cellular activities.
Towards this end, we generated a mouse strain with p53 gene harboring the human core domain sequence. In these mice, referred to as hupki mice (for human p53 knock-in), exons 4 ± 9 and intervening introns of the mouse allele have been replaced with the corresponding homologous segment of the normal human p53 gene, and transcription remains under endogenous control of the mouse locus. Biochemical and functional studies described here demonstrate that the genetically-modi®ed p53 gene of homozygous hupki mice is expressed at physiological levels and can perform various cellular functions of normal p53.
Results

Generation of human p53 knock-in (hupki) mice
After identi®cation of ES clones containing the recombinant allele (p53 KI ) of p53 ( Figure 1 , upper panel), ES cells were injected into blastocytes to generate chimeric mice. Germline transmission of the knock-in allele originally derived from ES clone 3 ± 16 was identi®ed by Southern blotting after breeding chimeric mice with wild-type mice (Figure 1 ). F1 germline heterozygous ospring (p53 KI/+ ) were intercrossed to produce F2 homozygous hupki mice. Both heterozygous and homozygous hupki mice from such crosses were born at the expected frequency (Mendelian ratio), and homozygous hupki mice are phenotypically normal and fertile (data not shown), suggesting that the chimeric p53 protein is compatible with mouse development. Homozygous hupki mice developed no spontaneous tumors by 8 months of age, in contrast to p53 null mice which are highly susceptible to lymphomas and sarcomas at an early age (Donehower et al., 1992; Jacks et al., 1994) .
To examine whether the chimeric p53 is transcribed correctly in vivo, p53 cDNA prepared from hupki (p53 KI/KI ) mouse spleen RNA was sequenced and shown to match precisely the mouse wild-type p53 gene sequence in exons 2, 3, 10 and 11, whereas exons 4 ± 9 (codons 33 ± 332) were identical to the normal human p53 sequence, as expected. The human polymorphic codon 72 encodes arginine in the p53 KI gene. The cDNA sequence con®rmed that the targeted chimeric gene is correctly spliced and transcribed in the spleen of hupki mice (data not shown).
Analysis of p53
KI gene expression
Our objective was to generate a mouse with a human/ mouse chimeric p53 gene at the endogenous locus that would remain under normal transcriptional regulation, and would maintain normal p53 tumor suppressorassociated functions. In view of the high divergence between mouse and human intron sequences, and their possible role in transcription regulation (Shamser and Montano, 1996) , we ®rst compared p53 mRNA levels in various tissues of 10-week-old wild-type (p53 ) and wild-type (p53 +/+ ) tissues using b-actin (reference sequence) and p53-speci®c primer pairs indicated similar levels of p53 expression for the two genotypes in each tissue compared ( Figure 2A ); p53 expression is high in spleen, thymus, lung and kidney, relative to levels in brain; (ii) restriction patterns of p53 RT ± PCR products: To corroborate that the p53 KI transcript is present in various tissues and at levels comparable to wild-type mice, we took advantage of AvaI restriction sites present in exon 6 of the normal mouse p53 gene, but absent in the human exon 6 sequence. RT ± PCR ampli®cations encompassing exon 6 and using template from p53 KI/+ heterozygotes, followed by enzymatic digestion with AvaI yielded comparable amounts of cleaved product (from the p53 + allele) and uncleaved product (from the p53 KI allele) for all 10 organs examined. (Results with liver and spleen are shown in Figure 2B ; data not presented for the eight additional tissues referred to in Figure  2A ); and (iii) Northern blotting: The presence of equivalent p53 mRNA levels in p53 KI/KI and p53 +/+ mice was veri®ed in thymus, spleen and brain (showing high, medium and low levels respectively) of 10-weekold mice by Northern blot analysis using exon 11 probe P (data not shown). The presence of hupki p53 protein, and its accumulation following DNA damage by g-irradiation were examined on immunoblots from primary embryonic ®broblast whole cell extracts using anti-mouse p53 polyclonal antibody CM5. As shown in Figure 3A , p53 KI protein from hupki cells is expressed, and levels increase following 5 Gy g-irradiation, as is seen with wild-type murine p53 (p53 + ). With CM5 antiserum, p53 signal intensity on immunoblots is lower in hupki and in human neonatal ®broblast extracts than in extracts from wild-type mice (data not shown), as anticipated from Pepscan ELISA analysis of CM5 (Lane et al., 1996) , so the issue of whether p53 protein levels are equivalent in wild-type and hupki cells is not addressed in this experiment. Electromobility shift assays (EMSA) with protein from irradiated primary , mouse genomic p53 sequences; Fragment B: selection cassette containing neo and TK genes; Fragment C, 2.8 kb human p53 segment encompassing human exons 4 ± 9 (aa 33 ± 332). Symbols: Solid squares: mouse exons; open squares: human exons; Open square`P': exon 11 probe (outside recombination junction) used for Southern and Northern blot hybridizations; solid horizontal arrows: 34 bp loxP sequence; restriction enzyme sites used or generated by cloning strategy or used in genotyping include: K, KpnI; X, XbaI; H, HindIII; S, SpeI, N, NotI; V, AvaI, G, BglII; M, BamHI. Lower panel: Genotyping of ES clones and mice by Southern blot analyses. Genomic DNA was isolated from ES clones or tails of hupki mice, and digested by BglII alone, or by BglII and BamHI, followed by hybridization to 32 P-labeled mouse exon 11 probe P (box marked`P'). BglII digestion: the wild-type allele (+) and knock-in allele (KI) (after excision of the neo/TK selection cassette by Cre) generate a 13 kb fragment, whereas the targeted allele before cassette excision generates the smaller 9 kb fragment due to a BglII site in the cassette. BglII/BamHI digestion: The untargeted endogenous p53 allele generates a 4.2 kb fragment, whereas both the targeted allele (before cassette excision), and the knock-in allele after cassette excision (KI), generate a 6.2 kb probe-hybridizing fragment. Note that probe P also hybridizes in all genotypes to a faster migrating fragment corresponding to the mouse p53 pseudogene. (A) ES cell genotyping: (B) mouse genotyping embryonic ®broblasts were performed to test whether the hupki protein is able to bind to p53 target DNA sequences, a pre-requisite for many tumor suppressor activities of p53. Experiments using p53 consensus oligonucleotide p53 CON and anti-p53 antibody PAb421 revealed speci®c complexes with hupki cell extracts, as was observed with complexes from wild-type cell extracts ( Figure 3B ). Speci®c competition with nonradioactive consensus sequence abolished the signal, whereas a 20-fold excess of mutant consensus sequence, which does not bind p53 protein had no eect on signal intensity ( Figure 3B ).
P53 functional analysis
Transcriptional regulation of numerous genes is critical to p53-mediated cell cycle arrest and apoptosis following DNA damage by g-irradiation. Speci®c transactivation of two well-studied genes, p21/Waf1/ Cip1, encoding a cyclin-dependent kinase, and Bax, a regulator of programmed cell death, was initially observed by semi-quantitative RT ± PCR in spleen of g-irradiated (5 Gy) wild-type and homozygous hupki mice 6 and 24 h post treatment (data not shown). Irradiation induction of Bax and p21/Waf1 was veri®ed in both genotypes by Northern blot analysis ( Figure 4A ). Gene expression pro®ling was performed with Clontech Mouse 1.2 Atlas TM membranes (41000 distinct cDNA sequences) for spleen of homozygous hupki mice to investigate concordance with wild-type pro®les. Expression patterns were highly similar in the two genotypes, both from untreated and from irradiated mice 24 h post treatment; Hupki spleen transcript levels of numerous genes involved in distinct cellular processes were induced by treatment, including p53-inducible genes Cyclin G, and Mdm2, consistent with expectations from the literature on p53 wild-type mice (Table 1) .
Wild-type p53 protein in normal cells accumulates in nuclei in response to ultraviolet light (UV)-induced DNA damage to levels readily detected by immunocytochemistry. We investigated this response to UV ) and heterozygous (p53 KI/+ ) mice, indicating equivalent levels of wild-type (with AvaI sites), and KI (no AvaI site) p53 transcripts. cDNA was ampli®ed by PCR using p53 primers P42A and P10B to generate an 836 bp product. AvaI digestion in exon 6 cleaves this product when cDNA is derived from wild-type mouse tissues but not when from hupki tissues. cDNA of p53 KI/+ heterozygote shows both cleaved and uncleaved fragments of approximately equal intensities on ethidium bromide-stained agarose electrophoresis gels. Symbols: U, undigested PCR product (836 bp); D: PCR product incubated with AvaI restriction enzyme, yielding two major fragments from wild-type fragment: 433 and 343 bp, (and 60 bp; not visible on gel photo) irradiation in hupki cells. Nuclei of hupki (p53 KI/KI ) embryonic ®broblasts exposed 24 h previously to 25 J/m 2 UV light (254 nm) revealed intense nuclear staining with polyclonal p53 antibody CM1, whereas nuclei of unirradiated control cell cultures showed faint to no signal with the same staining procedure ( Figure  4b ). This response is further indication that the hupki p53 protein is subject to this cellular regulation in a manner similar to wild-type p53.
P53-dependent and -independent apoptosis in thymocytes of hupki mice
To test whether the chimeric p53 protein would function in a p53-dependent biological process, we studied apoptosis induced by DNA damaging agents. Thymocytes were isolated from wild-type (p53 +/+ ), ) animals, and exposed to ionizing radiation ( Figure 5 ), which induces apoptosis that is dependent on functional p53, or to dexamethasone, which induces p53-independent apoptosis in this cell type. After treatment with dexamethasone, thymocytes from all three genotypes exhibited apoptosis with similar kinetics (Figure 5A ), indicating that this death pathway was not aected by the absence of wild-type p53 or the presence of hupki p53 protein. As expected, treatment with 5 Gy g-irradiation induced apoptosis in wild-type cells, whereas thymocytes from p53 7/7 mice were profoundly resistant to the eects of ionizing radiation ( Figure 5B ), consistent with previously published results (Lowe et al., 1993; Clarke et al., 1993) . Notably, thymocytes from hupki mice were susceptible to g-irradiation-induced apoptosis at the same levels as those in wild-type thymocytes. In addition, in a dose-response experiment, hupki thymocytes exhibited apoptosis after various doses of g-ray treatment with similar kinetics to wild-type cells at all doses tested ( Figure 5C ). These data indicate that the chimeric hupki p53 protein functions as eciently as wild-type p53 with respect to its role in thymocyte apoptosis. 
Discussion
We have generated a mouse strain in which human p53 gene sequences encompassing the p53 core domain are embedded in the endogenous p53 locus on mouse chromosome 11, and replace the corresponding mouse gene segment. We designed the targeting vector so that the entire core domain and anking sequences would be homogeneous with respect to species origin, since an engineered human/ murine chimeric core domain theoretically could present a sequence con®guration that would render various subsequent somatic missense mutations innocuous by an intragenic suppressor mechanism (Brachmann et al., 1998) . Expression and endogenous regulation of the modi®ed p53 gene (p53 KI ) have been achieved in homozygous hupki mice, despite the chimeric nature of the allele and the notorious sensitivity of p53 to minor sequence alterations not directed by evolution (Hainaut and Hollstein, 2000; Brachmann et al., 1998; Cho et al., 1994) .
It has been shown recently that arginine at the common Arg/Pro polymorphic residue 72 of human p53 can enhance tumorigenicity of certain p53 mutants by compromising control of apoptosis by p73b, a binding partner of p53 (Marin et al., 2000) . Since the hupki protein harbors the Arg72 residue, this raises the interesting possibility that presence of this residue will recapitulate the human situation by increasing tumorigenic potential of somatic mutations arising in mutagen-exposed hupki mice.
The biochemical and functional studies we have conducted thus far indicate we have achieved our aim to generate human p53 knock-in mice that retain in vivo physiological control of p53 and several of its functions. The hupki p53 KI/KI mice exhibit normal development, fertility, and a p53 phenotype thus far corresponding to wild-type p53 +/+ mice of the same genetic background. Expression pro®ling with Aymetrix TM gene expression arrays is underway to explore potential dierences between hupki and normal mice in the complex transcription patterns/ induction kinetics of p53-downstream genes (Yu et al., 1999) . Recent studies have demonstrated that distinct subsets of genes are regulated by p53 according to the nature of the inducing factor and cell type (Yu et al., 1999; Zhao et al., 2000) . We Regulators of apoptosis or other biological processes:
*Selected listing of Array cDNAs giving a 42.5-fold increase in signal; **GenBank Accession # Figure 5 Function of hupki p53 protein in thymocyte apoptosis. Thymocytes were treated with 1 mM dexamethasone (A), 5 Gy ionizing radiation (B), and various doses of irradiation (C), as indicated. Viability was assessed at indicated time points after treatment. For the dose-response analysis, viability of thymocytes was measured as 20 h after g-irradiation. Values represent average of triplicate assays and were normalized to the amount of viable cells remaining in untreated cultures derived from the same animals. One of two independent experiments is shown chose spleen tissue, g-irradiation, and 6 or 24 h posttreatment times for initial characterization of hupki mice; however, since a complexity of phosphorylation events and protein ± protein interactions govern p53 function (Prives and Hall, 1999) , further investigations using other parameters may reveal more subtle dierences between hupki and wild-type mice in posttranslational modi®cation, biological function, or kinetics of activation. An important aspect of p53 function to address in future experiments is the ability of hupki p53 protein to perform similarly to wild-type p53 as participant in processes of DNA repair and recombination (Albrechtsen et al., 1999; Dudenhoer et al., 1999) . Paradoxically, a hupki mouse de®ciency in p53`guardian of the genome' activities could enhance fortuitously the usefulness of this mouse model by rendering the strain more susceptible to tumorigenesis when exposed to carcinogenic DNA damaging agents.
Mutation spectra
In principle, hypotheses regarding mutation induction by speci®c cancer risk factors may be tested by comparing p53 tumor mutations typical of a de®ned high-risk patient group with mutations generated experimentally in rodents, or even in simple cell systems such as yeast (Hainaut and Hollstein, 2000, Dumaz et al., 1997; Flaman et al., 1994) . In practice, fundamental questions remain unanswered that require additional experimental models: In vivo`spontaneous' p53 mutation patterns in humans in dierent cell/tissue types, in in¯amed tissues, in regenerating tissues following toxicity or injury, or induced by oxidative stress, are ill-de®ned (Hollstein et al,. 1998; Beckman and Ames, 1998) . These are key issues, since for a number of common cancers it is unlikely that chemical carcinogens are a major contributor to the tumor p53 mutations observed (Hollstein et al., 1998; Baker et al., 1991) . The hupki mouse oers a new re®nement to p53 mutagenesis studies in rodents because it provides an in vivo rodent test model, yet with the precise human p53 sequence as mutation target. Various applications are open to investigators, such as detection of unselected mutations in normal tissues using sensitive PCR-based protocols (Aguilar et al., 1993) , mapping of DNA damage sites in the p53 gene to show colocalization of damage sites with human tumor mutation hotspots in the p53 gene (Denissenko et al., 1996) , or screening of neoplastic lesions and carcinomas in hupki mice for p53 core domain mutations with the Aymetrix p53GeneChip TM oligonucleotide array, an automated method applicable to hupki mouse samples because the p53 sequence is identical to the human sequence in exons 4 ± 9. Tumor mutation spectra from experiments in hupki mice can be compared directly to the published human tumor p53 mutation data, unlike p53 mutations pro®les that have been generated from examining tumors in wildtype mice.
Clinical implications
We anticipate that the hupki strain or its derivatives will pave the way for pre-clinical in vivo testing of new pharmaceuticals designed to modulate human p53 tumor suppressor DNA binding/transcription activation functions. The hupki strain facilitates further genetic re®nement involving, for example, recombinational exchange of amino or carboxy terminal p53 sequences, which also are of keen interest in the development of new therapeutic strategies (Hupp et al., 1995; Selivanova et al., 1997; Rodriguez et al., 1999) . Hupki strain derivatives carrying single point mutations discovered in Li-Fraumeni syndrome cancer-prone families (Kleihues et al., 1997) would provide a new mouse model with an allelic con®guration that parallels the human situation, and complement existing animal models with mutant mouse p53 transgenes or p53-de®cient genotypes (Donehower et al., 1992; Jacks et al., 1994; Hurstings et al., 1995; Zhang et al., 2000; Liu et al., 2000) .
Materials and methods
Construction of the gene-targeting vector
DNA fragments A, C, and D of the gene targeting vector (Figure 1 , upper panel) were obtained as follows: Fragments A' and D were cloned from a 129/Sv genomic library. PCRgenerated fragments (A, C), from template A' and normal human genomic DNA respectively, were cloned into pGEM (Promega) vectors and sequenced using Big Dye TM (Applied Biosystems International, ABI) dideoxy chain terminators and an ABI Gene Analyzer Model 310 to con®rm that no mutations were introduced by Pfu polymerase into coding or splice site sequences. Fragment B, comprising loxP-¯anked HSV-thymidine kinase (TK) and neomycin phosphotransferase (neo) gene sequences, was obtained from XbaI/HindIII digestion of plasmid pHR-1. Fragments A ± D then were introduced step-wise into a pBluescript KS II (Stratagene) plasmid to generate the targeting vector (Figure 1 , upper panel).
Gene targeting in embryonic stem (ES) cells and generation of hupki mice
After electroporation of the targeting vector into ES cells (E14.1) and selection, ES clones with homologous recombination events at the endogenous p53 locus were identi®ed by both PCR and Southern blotting analysis (Figure 1, lower  panel) . The correctly targeted ES clones were subjected to transfection with a Cre-expressing vector (pMC-Cre) which deletes the neomycin/TK cassette¯anked by loxP sites to generate the knock-in allele (abbreviated KI in Figures 1 ± 5) . Clones with recombinant mouse ± human p53 sequences were identi®ed, total RNA was isolated, and the p53 cDNA sequence veri®ed by dideoxy sequencing. Mouse-speci®c primers for sequencing, PCR or RT ± PCR are from Ushijima et al. (1995) unless otherwise indicated. Sequences of primers for human p53 segments are from Lehman et al. (1991) and from the Aymetrix p53 GeneChip TM protocol. ES clones were injected into blastocytes to generate chimeric mice. Germline ospring were identi®ed by Southern blotting analysis after breeding of chimeric mice with C57/BL/6 or 129/Sv wild-type mice (Figure 1, lower panel) . All experiments were performed using mice of mixed genetic background (129/Sv6C57BL/6).
Isolation and culture of primary mouse embryonic fibroblasts (MEFs)
Embryonic ®broblasts were isolated from embryos of intercrosses of p53 KI/+ mice at E13.5 mid-gestation and cultured as previously described (Wang et al., 1995) : Fetuses were dissected from uteri and digested ®ve times, 5 min each, with 0.25% trypsin (Gibco-BRL) at 378C. Cells were then transferred to tissue culture¯asks and cultured in standard DMEM medium supplemented with 10% fetal calf serum. Experiments were carried out with primary ®broblasts of each genotype (passages 2 ± 3), derived from embryos of the same litter.
RNA analysis by semiquantitative RT ± PCR, Northern blots, and Clontech cDNA arrays Total RNA was extracted for RT ± PCR or Northern analysis with an RNeasy Kit (Qiagen) according to supplier's instructions. First strand cDNA synthesis was accomplished with a Promega TM RT Kit. Duplex RT ± PCR of tissue RNA with primers speci®c for p53 (P42A, P52A, P10B, Ushijima et al., 1995) , p21/Waf1 (5'-CGGTCCCG TGGACAGTGAGC-3'; 5'-AAATCTGTCAGGC TGGTCTGCC-3'), Bax (5'-GCGT-CCA CCAAGAAGCTGAG-3'; 5'-CCAC CCTGGTCTTG-GATCCA-3'), b-tubulin (5'-GACAGTGTGGCAACCA-GATCG-3', 5'-GTACGGAAGCAGATGTCGTAG-3') and b-actin (5'-TGTGATGGTGGGAATGGGTCAG-3'; 5'-TTT-GATGTCACGCACGATTTC-3') was performed initially in 50 ml reaction volumes over a range of cycles (20 ± 35) in a thermal cycler using the following cycling conditions: 958C, 1 min; 608C, 1 min; 728C, 45 s. For Northern analysis, 10 ± 15 mg total RNA per lane were electrophoresed on formaldehyde-containing gels, transferred by capillary blot onto GeneScreenPlus TM (DuPont) nylon membranes and hybridized to speci®c probes; probe P was generated by PCR with 129/Sv mouse genomic DNA template and primers P11A (5'-ACCAAGAAGGGCCAGTCTAC-3') and P11B (5'-TGGAG-GATATGG ACCCTATG-3'); Bax-, p21-or b-actin (control) probes were generated using primers as given above for RT ± PCR. Washed blots were exposed to Amersham X-ray ®lm for 1 ± 7 days. cDNA Arrays: Procedures for obtaining RNA, cDNA and hybridization protocols for Clontech Atlas TM Mouse 1.2 Microarrays were as recommended by the manufacturer. Hybridized arrays were exposed to X-ray ®lm ( 32 P) for 3 ± 7 days, or to FujiImage TM plates ( 33 P) for PhosphorImager visualization. Data were evaluated by ArrayVision TM software (Imaging Research Inc., Canada).
Protein analysis by immunoblot and electromobility shift assay (EMSA)
P53 consensus sequence p53 CON , and p53 monoclonal antibody PAb421 were purchased from Santa Cruz Biotechnology. The assay was performed according to supplier's instructions, with 20 mg whole cell extracts from g-irradiated (5 Gy) ®broblasts, 6 h post-treatment. Unlabeled p53 CON (206) were used as speci®c competitor, and the p53 mutant oligonucleotide (206) (Santa Cruz) as non-speci®c competitor. Proteins for immunoblots were extracted from embryonic ®broblasts in RIPA buer (25 mM Tris pH 8.2, 50 mM NaCl, 0.1% SDS, 0.5% Nonidet P-40, 0.5% deoxycholate) containing Complete TM proteinase inhibitor cocktail (Boehringer Mannheim), followed by centrifugation through Qiagen`shredders'. Twelve mg protein per lane were loaded onto SDS ± PAGE gels, electrophoresed, and gels were blotted onto PVDF membranes. Primary antibodies or antisera used were CM5 (anti-p53, Novacastra, Newcastle upon Tyne, UK) or anti-laminin-b1 (C-19, Santa Cruz Biotechnology, CA, USA). Protein from the AP43a (p53 7/ 7 ) mouse embryo ®broblast cell line (neg. control), and from neonatal primary human foreskin ®broblasts (positive control) were examined in parallel.
Irradiation of whole mice and embryonic fibroblasts
Whole body g-irradiation (5 Gy) was performed on 10-weekold p53 +/+ , p53
KI/+ and p53 KI/KI mice. Mice were sacri®ced 6 or 24 h post-irradiation. Fibroblasts from embryos were obtained according to our previously published protocol (Wang et al., 1995) . Primary embryonic ®broblast monolayers were irradiated (5 Gy), and cultured an additional 6 or 24 h before extraction of RNA or protein. 
Apoptosis in thymocytes treated with DNA damaging agents
Thymocytes were isolated from wild-type, hupki, and p53 null mice at 6 weeks of age as previously described (Wang et al., 1995) , and adjusted to a density of 1610 6 cells per ml. At time zero, cultures were treated (see legend to Figure 5 ), distributed into 35 mm wells (1610 6 per well) and incubated at 378C. Apoptotic cells were stained with ApoAlert Annexin V Kit (Clontech, Palo Alto, CA, USA) reagents, and analysed with FACScan (Becton Dickinson).
Abbreviations hupki, human p53 knock-in mice; KI, knock-in allele
